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AbstrACt
Objectives Our central research question was, in England, 
are geographical inequalities in opioid use driven by health 
need (pain)? To answer this question, our study examined: 
(1) if there are regional inequalities in rates of chronic pain 
prevalence, pain intensity and opioid utilisation in England; 
(2) if opioid use and chronic pain are associated after 
adjusting for individual-level and area-level confounders.
Design Cross-sectional study design using data from the 
Health Survey for England 2011.
setting England.
Primary and secondary outcome measures Chronic 
pain prevalence, pain intensity and opioid utilisation.
Participants Participant data relating to chronic pain 
prevalence, pain intensity and opioid usage data were 
obtained at local authority level from the Health Survey for 
England 2011; in total, 5711 respondents were included in 
our analysis.
Methods Regional and local authority data were mapped, 
and a generalised linear model was then used to explore 
the relationships between the data. The model was 
adjusted to account for area-level and individual-level 
variables.
results There were geographical variations in chronic 
pain prevalence, pain intensity and opioid utilisation across 
the English regions—with evidence of a ‘pain divide’ 
between the North and the South, whereby people in the 
North of England more likely to have ‘severely limiting’ or 
‘moderately limiting’ chronic pain. The intensity of chronic 
pain was significantly and positively associated with the 
use of opioid analgesics.
Conclusions There are geographical differences in 
chronic pain prevalence, pain intensity and opioid 
utilisation across England—with evidence of a ‘pain 
divide’. Given the public health concerns associated 
with the long-term use of opioid analgesics—and their 
questionable activity in the management of chronic pain—
more guidance is needed to support prescribers in the 
management of chronic pain, so the initiation of opioids 
can be avoided.
IntrODuCtIOn
Chronic pain is a worldwide problem, and the 
burden it places on our society is increasing: 
in the USA, the annual cost of chronic 
pain—through direct and indirect effects—
is estimated to exceed US$500 billion, while 
in the UK estimates suggest it costs around 
£12 billion per year to the economy.1 2 To 
manage the symptoms associated with chronic 
pain, some treatment strategies rely on the 
use of opioid analgesics, although there are 
very few studies to support their long-term 
effectiveness.3–5 In addition, prolonged use of 
opioids can also have adverse consequences; 
this can include sleep disturbances, endo-
crine disorders, reduced immune function 
and increased pain through opioid-induced 
hyperalgesia.6–10 
Despite these well-acknowledged short-
comings, the prescribing of opioid analgesics 
continues to increase at a significant rate.11 12 
Indeed, figures from the UK show that, in 
2014, there were around 23 million prescrip-
tions written for opioid analgesics, at a cost of 
around £322 million.13 Given this increased 
use, (and the well-established problems asso-
ciated with efficacy, tolerance and adverse 
effects) the inappropriate prescribing—and 
misuse—of opioid analgesics is becoming 
a significant public health concern.14 This 
problem is also mirrored in other coun-
tries, such as the USA, where the death rate 
from opioid misuse has, in the last 15 years, 
quadrupled—giving rise to the so-called 
‘opioid epidemic’.15
strengths and limitations of this study
 ► This study is unique in that we explored the associa-
tion of opioid utilisation and chronic pain.
 ► We adjusted for individual (eg, age and sex) and 
area-level confounders (eg, social deprivation) in our 
model.
 ► We did not distinguish between weak and strong 
opioid in our analysis, nor did we consider dose of 
opioid.
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In England, there is significant geographical variation 
in opioid prescribing—with more people in the North 
of England prescribed opioids—at a greater cost—
compared with the rest of England. For example, the 
North of England (population of 15 million) accounts 
for approximately 33% of the total costs of analgesics, 
compared with London (population of 8.2 million), that 
accounts for only around 8%.12 It is not clear, however, 
if this variation is related to ‘inappropriate prescribing’ 
or the varying health need of the population (ie, more 
people in the North of England have pain, hence the 
prescribing of opioids is higher). It is well documented, 
though, that mortality and morbidity rates are higher 
in the North of England, particularly in the North East 
region compared with the rest of England: an observation 
known as the North South health divide.16
Northern England (commonly defined as the North 
East, North West and Yorkshire and Humber regions) has 
persistently had higher all-cause mortality rates than the 
South of England, with people in the North consistently 
found to be less healthy than those in the South—across 
all social classes and among men and women.17 Since 
1965, this has amounted to 1.5 million excess prema-
ture deaths.18 Further, the gap in average life expec-
tancy between the North and the South of England is 2 
years.16 Although England is not alone in experiencing 
such spatial health inequalities, the divide in England is 
one of the largest in Europe—greater, for example, than 
those between the former East and West of Germany.19 
Social science suggests that the reasons for the contem-
porary health divide are both compositional and contex-
tual.16 Compositional factors include demographic factors 
(eg, age, sex, marital status) and socioeconomic status 
(eg, employment, income, education, occupation), as 
well as health behaviours (eg, smoking, alcohol, physical 
activity). In the case of pain, other compositional factors 
will include comorbidities such as depression or anxiety. 
Contextual factors include the physical (eg, air pollution 
or contaminated land),20 social (eg, place-based stigma or 
social networks or access to services such as general prac-
titioners)21 and economic (eg, area-level deprivation, local 
job availability) environments.22
Given the North South health divide and public health 
concerns associated with the inappropriate and long-term 
use of opioid analgesics, it is vitally important then to 
explore whether the prescribing of opioid analgesics across 
England reflects inequalities in the health needs of the 
population (pain) or if there is an issue of ‘inappropriate’ 
medication prescribing or utilisation. Our central research 
question, therefore, was, in England, are geographical 
inequalities in opioid use driven by health need (pain)? 
To answer this question, our study examined: (1) if there 
are regional inequalities in rates of chronic pain preva-
lence, pain intensity and opioid utilisation in England; (2) 
if opioid use and chronic pain are associated after adjusting 
for individual-level and area-level confounders.
MethODs
Data and variables
Local authority level Health Survey for England (HSE) 
data were obtained from the National Centre for Social 
Research, which contains anonymised individual-level 
data and a geographical identifier (local authority district 
which are large administrative areas used by local govern-
ment in England and have the responsibility for health 
and social care, education, transport and so forth). The 
HSE is an annual survey designed to be representative 
using a stratified random sample. Each year there is a 
focus on a particular population group, condition or 
disease. In 2011, one particular focus of the HSE was 
detailing chronic pain: as part of the wider survey, partic-
ipants were asked:
 ► Whether they were currently troubled by pain or 
discomfort?
 ► Whether they had this pain or discomfort for more 
than 3 months?
If the respondent answered yes to both questions, they 
were categorised as experiencing chronic pain. Once it 
was established that participants had chronic pain, they 
were then asked a further three questions:
 ► How would you rate your pain right now, on a scale 
from 0 to 10, where 0 is no pain and 10 is pain as bad 
as it could be?
 ► In the last 3 months, how would you rate your worst 
pain, on a scale from 0 to 10, where 0 is no pain and 
10 is pain as bad as it could be?
 ► On average, in the last 3 months, how would you rate 
your pain on a scale from 0 to 10, where 0 is no pain 
and 10 is pain as bad as it could be?
The answers to these questions were then used to 
compute a variable on pain intensity on a scale of 0–4, 
indicating ‘grade 0—no intensity (ie, no chronic pain)’, 
‘grade 1—low intensity’, ‘grade 2—high intensity’, grade 
3—moderately limiting’, ‘grade 4—severely limiting’. 
This grading was based on the 3-item Graded Chronic 
Pain-Pain Catastrophizing Scale.23 Sociodemographic 
variables included were age, sex, marital status, highest 
educational qualifications, occupational classifications, 
household income quintile. Health-related data included 
self-assessed general health status (very good, good, fair, 
bad, very bad), presence of mental health disorder (yes/
no), anxiety levels (not anxious or depressed, moderately 
anxious or depressed, extremely anxious or depressed) 
and ranking of happiness on a 0–10 scale. Opioid usage 
data were also contained in the 2011 HSE. Area-level 
deprivation data included the Index of Multiple Depri-
vation (IMD) 2010 obtained from the HSE. The IMD 
produces a ranking of areas in England based on relative 
local scores for: income, employment, health, education, 
crime, access to services and living environment. IMD was 
included because there is a strong relationship between 
area-level deprivation and mortality and morbidity—
with the most deprived neighbourhoods in England 
experiencing life expectancy 9 and 6 years less for men 
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and women, respectively, than those that are the least 
deprived.24
The English regions were classified as the North (North 
East, North West, Yorkshire and the Humber) and the South 
(London, East of England, West Midlands, East Midlands, 
South East and South West). This study used individual-level 
HSE data, and therefore, HSE survey weights applicable for 
individual-level data were used.
Data analysis
Chronic pain prevalence, pain intensity and opioid usage 
were mapped using Adobe Illustrator with local and 
regional boundaries downloaded from the Office for 
National Statistics. In the HSE, opioid use was described as 
a binary variable (a yes or no response), and was used as 
an outcome variable to examine the association between 
opioid use and factors associated with it. The HSE 2011 
individual-level data had 10 617 cases, and pain data were 
only collected among respondents aged 16 years and over 
(n=8610). Cases where there were missing values for the 
confounding variables (regions, age, sex, marital status, 
highest educational qualification, occupational level, 
household income quintiles, general health status, mental 
health disorders, anxiety levels and happiness scale) were 
then excluded from our analysis. Missing values in the HSE 
can occur for several reasons, including refusal or inability 
to answer a particular question or refusal to cooperate in an 
entire section of the survey. After this, the dataset with no 
missing values (n=5711) was used in our analysis. Variables 
that showed significant bivariate association were included 
in the initial model. Apart from the presence of chronic 
pain and pain intensity, the initial model included age, sex, 
marital status, highest educational qualification, occupa-
tional level, household income quintiles, general health 
status, mental health disorders, anxiety levels and happi-
ness scale. A generalised linear model with binomial distri-
bution and logit link was used to examine the associations 
between opioid use and chronic pain, adjusted for individu-
al-level and area-level covariates. Survey weight was applied 
to the model. The most parsimonious model was obtained 
by using likelihood ratio test statistics to ensure there was 
no significant loss of information. To support the spatial 
analysis of a ‘pain divide’ between the North and the South 
of England, the pain intensity data were analysed using a 
generalised logit model to simultaneously analyse the four 
logit models resulting from the five levels of the pain inten-
sity data (no pain, low intensity, high intensity, moderately 
limiting and severely limiting). Although the pain intensity 
is ordinal, the proportional odds model is both intuitively 
and statistically not appropriate because of the assumption 
of the common odds between the levels of pain intensity 
data. Survey weight was used in all analyses to ensure gener-
alisation of findings.
This study was undertaken and reported according 
to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) recommendations.25 
Data analysis was done using SAS v.9.4.
Patient and public involvement
As this study involved secondary data analysis from the 
HSE, patients or the public were not involved in the 
design or delivery of this research.
results
regional inequalities in the prevalence of chronic pain, pain 
intensity and opioid use in england
The prevalence of chronic pain was 36.7% in the North 
of England, compared with the 35.0% in the South of 
England, as shown in table 1, and visually in figure 1. 
In terms of the nine English regions, the prevalence of 
chronic pain was highest in the North East, and lowest 
in London (43.1% vs 29.0%). In terms of pain inten-
sity, 9.2% of people living in the South had ‘moderately 
limiting’ or ‘severely limiting’ chronic pain, while, in the 
North, 12.3% of people had ‘moderately limiting’ or 
‘severely limiting’ chronic pain. People in the North were 
also more likely to experience ‘moderately limiting’ or 
‘severely limiting’ pain than those in the South: the odds 
of severely limiting pain were 32% higher in the North 
than in the South; similarly, the odds of ‘moderately 
limiting’ pain were 37% higher in the North than the 
South, as shown in table 2. In addition to differing pain 
levels in the North and South English regions, there were 
also observed differences in anxiety and self-reported 
general health: anxiety levels in the North were 27.3%, 
compared with 25.7% in the South, while for self-re-
ported general health, 7.6% and 5.5% of people living 
in the North and South, respectively, were reported to 
have ‘bad’ or ‘very bad’ health status. Although chronic 
pain prevalence was similar in the North and South of 
England (36.7% and 35.0%, respectively), opioid use 
was somewhat higher in the North (2.5%), compared 
with the South (1.7%). Furthermore, the use of opioids 
(weighted results) was higher in the North of England 
for people with ‘severely limiting’ chronic pain (16.9%), 
compared with people in the South (10.4%), as illus-
trated by figure 2.
Association of opioid utilisation and chronic pain after 
adjusting for individual-level and area-level confounders
Opioid usage was significantly associated with chronic 
pain intensity (adjusted for age, household income, 
education level, general health and anxiety): in people 
with higher pain intensities, there were higher odds of 
opioid use, as illustrated by table 3. The use of opioids was 
also positively associated with household income levels: 
households belonging to the higher income quintiles 
had significantly higher odds of using opioids than those 
at the lowest quintile. In addition, general health status 
was significantly positively associated with opioid usage: 
people who reported ‘very bad’ or ‘bad’ health status had 
14% higher odds, and 6% higher odds of using opioids, 
respectively, compared with those who reported ‘very 
good’ health status. 
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Table 1 Characteristics of the study population
Variable South % (n) North % (n) Overall % (n)
Region 68.2 (3896) 31.8 (1815) 100.0 (5711)
Age group 
  Median (25th, 75th percentile) 45 (32, 60) 45 (32, 60) 45 (32, 60)
Sex 
  Female 55.9 (2178) 55.3 (1003) 55.7 (3181)
  Male 44.1 (1718) 44.7 (812) 44.3 (2530)
Marital status 
  Single 25.5 (995) 27.7 (503) 26.2 (1498)
  Married/civil partner 55.8 (2173) 50.7 (921) 54.2 (3094)
  Divorced/widowed/ 
separated
18.7 (728) 21.5 (391) 19.6 (1119)
Anxiety grades 
  Extreme 2.2 (85) 2.9 (53) 2.4 (138)
  Moderate 23.5 (917) 24.4 (443) 23.8 (1360)
  Not anxious 74.3 (2894) 72.7 (1319) 73.8 (4213)
Income quintiles 
  Highest 25.1 (977) 16.4 (297) 22.3 (1274)
  Second highest 22.7 (884) 20.2 (367) 21.9 (1251)
  Middle 19.9 (775) 20.6 (374) 20.1 (1149)
  Second lowest 18.2 (708) 25.1 (455) 20.4 (1163)
  Lowest 14.2 (552) 17.7 (322) 15.3 (874)
Occupation 
  Managerial and professional 40.2 (1566) 34.2 (620) 38.3 (2186)
  Intermediate 25.2 (982) 21.5 (390) 24.0 (1372)
  Routine and manual 31.0 (1209) 40.9 (743) 34.2 (1952)
  Other 3.6 (139) 3.4 (62) 3.5 (201)
Educational qualifications 
  No qualifications 17.3 (674) 21.8 (395) 8.7 (1069)
  Foreign/other 1.4 (54) 1.5 (27) 1.4 (81)
  NVQ level 1 or equivalent 4.0 (155) 4.7 (86) 4.2 (241)
  NVQ level 2 or equivalent 22.2 (864) 22.0 (399) 22.1 (1263)
  NVQ level 3 or equivalent 15.6 (608) 15.4 (279) 15.5 (887)
  NVQ level 4 or equivalent 11.9 (462) 12.2 (222) 12.0 (684)
  NVQ level 5 or equivalent 27.7 (1079) 22.4 (407) 26.0 (1488)
General health 
  Very bad 1.3 (52) 2.3 (42) 1.6 (94)
  Bad 4.2 (165) 5.3 (96) 4.6 (261)
  Fair 15.6 (607) 18.2 (330) 16.4 (937)
  Good 44.1 (1719) 42.8 (776) 43.7 (2495)
  Very good 34.7 (1353) 31.5 (571) 33.7 (1924)
Mental health disorder 
  No condition 96.0 (3741) 95.6 (1735) 95.9 (5476)
  Has condition 4.0 (155) 4.4 (80) 4.1 (235)
Happiness scale 
  Median (25th, 75th percentile) 8 (7,9) 8 (7,9) 8 (7, 9)
Continued
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DIsCussIOn
This paper is the first to examine geographical inequali-
ties in chronic pain prevalence, pain intensity and opioid 
utilisation in England. It is also the first to examine the 
association between chronic pain intensity and opioid 
utilisation. We have identified two key findings that 
may be of importance to healthcare practitioners and 
policy-makers: (1) there are geographical variations in 
chronic pain prevalence, pain intensity and opioid utilisa-
tion across the English regions—with evidence of a ‘pain 
divide’ with people in the North of England more likely 
to have higher intensity of pain; (2) opioid utilisation 
was significantly, and positively associated with pain 
intensity. The higher prevalence and intensity of pain in 
the Northern regions, as well as a higher percentage of 
people belonging to lower education groups may only 
partly explain the higher rates of opioid usage found 
there. However, the number of people who used opioids 
in the survey was too small to support an interaction 
model between pain intensity and regions or a separate 
subgroup analysis for each region. These findings suggest 
the reason why people in the North East of England are 
prescribed more opioid analgesics than other parts of 
England is owing to the higher health need (pain). This 
Variable South % (n) North % (n) Overall % (n)
Weighted results with 95% CIs and numbers 
Opioid use 
  No 98.3 (97.9 to 98.7; n=3897) 97.5 (96.8 to 98.3; n=1577 98.1 (97.7 to 98.5; n=5474)
  Yes 1.7 (1.3 to 2.1; n=66) 2.5 (1.7 to 3.3; n=40) 1.9 (1.5 to 2.3; n=106)
Chronic pain intensity 
  None 65.0 (63.5 to 66.5; n=2574) 63.3 (60.9 to 65.6; n=1024) 64.5 (63.2 to 65.7; n=3598)
  Low intensity 1.7 (1.3 to 2.1; n=66) 1.4 (0.8 to 1.9; n=22) 1.6 (1.3 to 1.9; n=88)
  High intensity 24.2 (22.8 to 25.5; n=958) 23.0 (21.0 to 25.1; n=373) 23.8 (22.7 to 24.9; n=1331)
  Moderately limiting 3.4 (2.8 to 3.9; n=134) 4.3 (3.3 to 5.3; n=69) 3.6 (3.1 to 4.1; n=203)
  Severely limiting 5.8 (5.1 to 6.6; n=231) 8.0 (6.7 to 9.4; n=130) 6.5 (5.8 to 7.1; n=361)
Table 1 Continued 
Figure 1 Prevalence of chronic pain by local authority and English region.
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is in keeping with wider studies of regional inequalities 
in health16 and is a potentially important and significant 
finding given the recent public health concerns associ-
ated with opioid analgesics.
While this is the first study to examine the relation-
ship between chronic pain intensity and opioid usage in 
England, there have been other studies that have explored 
the geographical variation in opioid prescribing. For 
example, a recent study by Mordecai et al showed that, at a 
clinical commissioning group level, over a 4-year period, 
there was an increasing trend of opioid prescribing—
with more opioid analgesics prescribed in the North of 
England, compared with the South.26 Our work builds 
on these findings, and shows that the increased trend of 
opioid prescribing is associated with an increase in health 
need (pain), rather than an ‘inappropriate’ prescribing 
trend of opioid analgesics. In addition to this, there have 
been a number of studies that have explored prescribing 
variation in other parts of the world, such the USA,27 28 
Canada29 and Australia30; these studies have also showed 
there is a large geographical variation in prescribing 
practices of opioid analgesics, and call for guidance 
to promote good prescribing practices. Our results are 
timely, and show that, in England, the prescribing of 
opioid analgesics is largely driven by health need (pain); 
thus, to develop future strategies going forward, and 
avoid a potential ‘opioid epidemic’, as observed in the 
USA, it is important that consideration is given to other 
ways of managing chronic pain, without the use of opioid 
analgesics. While opioids may have a role in the short-
term management of pain, their long-term use is ques-
tionable.6–10 Currently, national guidelines recommend 
strong opioids as an option for pain relief for patients 
with chronic pain, providing they are reviewed annually, 
and only continued if they are providing ongoing pain 
relief.31 While this is helpful in some instances, it is often 
difficult to ascertain, in a clinical setting, if opioid anal-
gesics continue to provide ongoing pain relief; patients 
using opioids are also often reluctant to reduce or stop 
their opioid medication.32 33 Studies also show that opioid 
discontinuation is associated with reducing pain scores; 
opioid-induced hyperalgesia also reduces on opioid cessa-
tion, which can further reduce levels of pain.34 Given our T
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Figure 2 Opioid use among participants from the North and 
South of England according to chronic pain grades.
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findings, more needs to be done—at a national level—to 
support prescribers to manage people who have chronic 
pain, without the need to initiate opioid analgesics. 
Another option that could potentially be used along-
side this approach would be to consider how opioids are 
monitored and stopped in the community. We note the 
recent attention given to the term ‘deprescribing’—a 
term used to describe the process of reducing or stopping 
inappropriate medication, with a view to minimising poly-
pharmacy and improving patient outcomes.35 It would be 
prudent to suggest that future prescribing strategies for 
opioids should also include an element of ‘deprescribing’ 
to ensure that if opioids are to be initiated, patients do 
not continue to use or be prescribed opioids for chronic 
pain indefinitely without benefit.
Our findings relating to geographical inequalities in 
chronic pain are in keeping with research into a number 
of other health outcomes, such as obesity, diabetes, 
cancer and cardiovascular disease, where higher rates 
are reported in the North—and in particular the North 
East—compared with the other English regions.16 Our 
work suggests that the North South health divide could 
increase in the future unless prescribing practices change 
because current guidance for using opioids to manage 
pain means that the North will have a higher burden 
of adverse effects in the future. Further, with an ageing 
population and an associated increase in chronic condi-
tions, then we anticipate a further increase in pain and 
therefore opioid use. Again, given the regional inequali-
ties in the burden of disease, this could exacerbate further 
the North South divide. This is timely, as the recent Due 
North report,18 an independent inquiry, commissioned 
by Public Health England, to identify actions that can 
reduce the gap in health between the North and South 
of England suggests that an urgent holistic approach is 
needed to ensure that future investment is effective at 
reducing inequalities. Our study shows that examination 
of the need for continued opioid prescribing should 
be considered in any strategies going forward to tackle 
the poorer health outcomes commonly reported in the 
North East of England, compared with the rest of the 
country.
Table 3 Generalised linear model examining associations between opioid use and chronic pain
Variables Categories OR (95% CIs) P values
Intercept 0.970 (0.956 to 0.985) <0.001
Age 1.000 (1.000 to 1.000) 0.112
Pain grade Severely limiting 1.078 (1.060 to 1.097) <0.001
Moderately limiting 1.036 (1.016 to 1.056) <0.001
High intensity 1.022 (1.013 to 1.031) <0.001
Low intensity 0.995 (0.968 to 1.023) 0.746
No chronic pain Ref
Income quintile Highest quintile 1.017 (1.004 to 1.030) 0.008
4th 1.018 (1.006 to 1.030) 0.004
3rd 1.018 (1.006 to 1.030) 0.003
2nd 1.016 (1.004 to 1.028) 0.007
Lowest quintile Ref
Highest qualification No qualification 1.012 (1.000 to 1.024) 0.059
Foreign/other 1.005 (0.972 to 1.039) 0.761
NVQ level 1 or equivalent 1.002 (0.984 to 1.021) 0.809
NVQ level 2 or equivalent 1.004 (0.994 to 1.015) 0.400
NVQ level 3 or equivalent 1.011 (1.000 to 1.022) 0.050
NVQ level 4 or equivalent 1.005 (0.992 to 1.017) 0.461
NVQ level 5 orequivalent Ref
General health Very bad 1.137 (1.102 to 1. 174) <0.001
Bad 1.057 (1.035 to 1.080) <0.001
Fair 1.022 (1.010 to 1.034) <0.001
Good 1.000 (0.992 to 1.008) 0.995
Very good Ref
Anxiety Extreme 1.015 (0.991 to 1.039) 0.227
Moderate 1.008 (1.000 to 1.017) 0.052
Not anxious Ref
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In terms of study limitations, we acknowledge that 
there are several: first, in our analysis, we used chronic 
pain prevalence and pain intensity as the marker for 
health need. Opioids are also used in the management 
of other conditions, such as acute postoperative pain, 
cancer pain or in the management of opioid substance 
dependence; clearly, this will have an influence regarding 
opioid prescribing practices. Also, the analysis does not 
discriminate between specific opioids, potency of opioid 
(eg, strong opioids vs weak opioids) or opioid dosages. 
It is also important to consider that geographical scale is 
important when exploring variation among a given area: 
it is possible that, even at local authority level, the opioid 
prevalence estimates are concealing further geographical 
patterning since they still contain relatively large popu-
lations. A finer scale analysis may, therefore, highlight 
particular opioid ‘hotspots’ where opioid prescribing and 
utilisation is concentrated. Another study limitation is that 
the HSE data were from 2011, although we note this is the 
most recent and meaningful data on chronic pain prev-
alence and pain intensity. Finally, the usual limitations 
of using cross-sectional data apply to this study meaning 
that we cannot claim causation only association. While we 
believe our results are robust, and have important policy 
implications, they should be interpreted cautiously in 
view of our acknowledged limitations.
COnClusIOn
There are geographical differences in chronic pain 
prevalence, pain intensity and opioid utilisation across 
England—with evidence of a ‘pain divide’ with people 
in the North of England more likely to have ‘severely 
limiting’ or ‘moderately limiting’ chronic pain. In our 
model, the intensity of chronic pain was significantly, 
and positively associated with the use of opioid analge-
sics. Given the public health concerns associated with 
the long-term use of opioid analgesics—and their ques-
tionable activity in the management of chronic pain—
more guidance is need to support prescribers in the 
management of long chronic pain, so the initiation of 
opioid can be avoided. Future opioid prescribing strat-
egies should also consider incorporating deprescribing 
approaches to ensure when opioids are initiated, their 
use is regularly monitored, reviewed and discontinued 
in the community.
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